In this week’s EuroBiotech Report, Novartis is getting deeper into the Israeli biotech scene, tasking BioLineRx with keeping tabs on local startups after realizing it was underexposed to the country. Alzheimer’s Research UK thinks it will find the next dementia drug in the “golden triangle” of Cambridge, London and Oxford. And more.

…read more

Source: Novartis makes Israel a priority, U.K. dreams up Alzheimer’s R&D hub, Shire defends tax model


0 No comments